Publications by authors named "Nikolaas De Neve"
Objectives: Circulating calprotectin (cCLP) has been shown to be a promising prognostic marker for COVID-19 severity. We aimed to investigate the prognostic value of serial measurements of cCLP in COVID-19 patients admitted to an intensive care unit (ICU).
Methods: From November 2020 to May 2021, patients with COVID-19, admitted at the ICU of the OLV Hospital, Aalst, Belgium, were prospectively included.
Introduction: Sepsis and septic shock cause significant mortality worldwide, with no targeted molecular therapies available. Metformin has pleomorphic effects that may be beneficial in sepsis, but at present, the impact of metformin exposure on sepsis remains controversial. Metformin might alter lactate metabolism, but little is known about its influence on lactate kinetics.
View Article and Find Full Text PDFArticle Synopsis
- A multicenter randomized controlled trial evaluated the efficacy and safety of the C5 inhibitor zilucoplan in hospitalized COVID-19 patients with systemic inflammation and hypoxemia.
- Out of 81 participants, those receiving zilucoplan showed greater improvement in oxygen levels compared to the control group, with a mortality rate of 9% versus 21% at day 28.
- Although the results were not statistically significant, findings suggest potential benefits of C5 inhibition for respiratory function and clinical outcomes, warranting further investigation in larger studies.
Article Synopsis
- The study investigated the use of circulating calprotectin (cCLP) as a biomarker to predict the severity of COVID-19, comparing it to other established biomarkers like IL-6 and CRP.
- Higher levels of cCLP were found in COVID-19 patients, especially those with severe conditions, ICU admissions, and those requiring mechanical ventilation, but it did not correlate with patients who died within 30 days.
- The results suggest that measuring cCLP can be useful for predicting the clinical progression of COVID-19, with EDTA and citrate plasma cCLP showing better discriminatory power than heparin plasma levels.
Target-Controlled Infusion of Cefepime in Critically Ill Patients.
Antimicrob Agents Chemother
December 2019
Attainment of appropriate pharmacokinetic-pharmacodynamic (PK-PD) targets for antimicrobial treatment is challenging in critically ill patients, particularly for cefepime, which exhibits a relative narrow therapeutic-toxic window compared to other beta-lactam antibiotics. Target-controlled infusion (TCI) systems, which deliver drugs to achieve specific target drug concentrations, have successfully been implemented for improved dosing of sedatives and analgesics in anesthesia. We conducted a clinical trial in an intensive care unit (ICU) to investigate the performance of TCI for adequate target attainment of cefepime.
View Article and Find Full Text PDFBackground: Electromyographic activity of the diaphragm (EMGdi) during weaning from mechanical ventilation is increased after sugammadex compared with neostigmine.
Objective: To determine the effect of neostigmine on EMGdi and surface EMG (sEMG) of the intercostal muscles during antagonism of rocuronium block with neostigmine, sugammadex and neostigmine followed by sugammadex.
Design: Randomised, controlled, double-blind study.
Objectives: Several population pharmacokinetic models for cefepime in critically ill patients have been described, which all indicate that variability in renal clearance is the main determinant of the observed variability in exposure. The main objective of this study was to determine which renal marker best predicts cefepime clearance.
Methods: A pharmacokinetic model was developed using NONMEM based on 208 plasma and 51 urine samples from 20 ICU patients during a median follow-up of 3 days.
Background: The use of neuromuscular blocking agents has been associated with severe postoperative respiratory morbidity. Complications can be attributed to inadequate reversal, and reversal agents may themselves have adverse effects.
Objective: To compare the electromyographic activity of the diaphragm (EMGdi) during recovery from neuromuscular blockade using neostigmine and sugammadex.
Background: The authors hypothesized a difference in plasma-effect site equilibration, depicted by a first-order constant k(e0), depending on the injection rate of propofol.
Methods: Sixty-one patients received 2.5 mg/kg propofol given as a bolus or as a 1-, 2-, or 3-min infusion.
Case reports mention a sudden awakening from GHB-associated coma but do not specify its time course. The aim of the present case series was to investigate the time course of the awakening from GHB intoxication and the relationship to plasma concentrations of GHB and the presence of other drugs. Unconscious (GCS